COMMUNIQUÉS West-GlobeNewswire

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure
17/10/2025
MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
17/10/2025
TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox TNX-801 demonstrated favorable safety, immunogenicity, and long-term protection in multiple [...]
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
17/10/2025
Conference call and webcast to discuss results to be held on November 7, 2025 at 8:00 a.m. ET IRVINE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an [...]
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
17/10/2025
Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up clinical data for [...]
Communiqué de presse : Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
17/10/2025
Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte Paris le 17 octobre 2025. Le Comité des médicaments à usage humain (CHMP [...]
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
17/10/2025
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) [...]
AB Science annonce le succès d'un placement privé de 2,8 millions d'euros
17/10/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE D’ENVIRON 2,8 MILLIONS D’EUROS AB SCIENCE EST ENTIEREMENT FINANCEE POUR TERMINER LA PHASE 1 DE L'ETUDE AB8939 DANS LA LMA ET POUR EXECUTER UNE PHASE [...]
AB Science announces the successful completion of a EUR 2.8 million private placement
17/10/2025
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.8 MILLION PRIVATE PLACEMENT AB SCIENCE IS FULLY FINANCED TO FINISH PHASE 1 OF AB8939 IN AML AND TO EXECUTE AN EXPANSION PHASE TO MAXIMIZE CHANCE OF [...]
atai Life Sciences Announces Pricing of Public Offering of Common Shares
17/10/2025
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health [...]
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
17/10/2025
NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that [...]
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering
17/10/2025
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
IBA ouvre la voie des sciences et des technologies aux jeunes filles du secondaire
17/10/2025
L’événement Innovat’her a réuni des étudiantes pour leur faire découvrir les carrières dans les STIM Louvain-la-Neuve, Belgique, le 17 octobre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial de la [...]
IBA opens the world of science and technology to secondary school girls
17/10/2025
Its Innovat’her event brought together female students to explore careers in STEM Louvain-la-Neuve, Belgium, October 17, 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator [...]
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
17/10/2025
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
The Hemp Doctor Debuts 6.5G THC Disposable Vape: Bolder & Stronger Than Ever
17/10/2025
MOORESVILLE, N.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, a trusted leader in premium dispensary-grade hemp-derived products, has unveiled its latest innovation: the PHUK’D UP MEGA 6.5G THC Blend Disposable [...]
Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
17/10/2025
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Le R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire
16/10/2025
○ Efficacité : taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22) ; 83 % à la dose recommandée de Phase 2 (RP2D, n=12) ; et 100 % dans la population cible de Phase 2 (n=9) 1 ○ Sécurité : en [...]
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
16/10/2025
○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 [...]
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
16/10/2025
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Pages